by BioKier | Mar 6, 2014 | Recent News
BioKier, Inc. has entered into an exclusive license agreement with UCL Business PLC (UCLB) for the proprietary colon delivery technology (PhloralTM) developed by researchers at the UCL School of Pharmacy. PhloralTM will be used in the formulation of an anti-diabetes...
by BioKier | Feb 21, 2014 | Recent News
BioKier was one of five selected North Carolina biotech companies to present in the Innovation Showcase session at the 2014 CED Life Science Conference in Raleigh on February 26-27. The selection included an invitation to present to attendees a report on BioKier’s...
by BioKier | Dec 30, 2013 | Recent News
BioKier will present at Biotech Showcase™ 2014 in San Francisco, January 13-15, 2014 Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and...
by BioKier | Jul 24, 2013 | Recent News
For Immediate Release: Contact: Roger Nolan, PhD, President BioKier — 919-270-2361 [email protected] Chapel Hill, NC, July 24, 2013 — BioKier, a privately held development-stage pharmaceutical company focused on the treatment of diabetes, announced...
by BioKier | Jun 27, 2013 | Recent News
US PTO has granted BioKier patent 8,470,885 which published on June 25, 2013
